Xuanzhu Biopharmaceutical Co., Ltd. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies. It specializes in digestive diseases, oncology, and non-alcoholic steatohepatitis (NASH), with over ten drug assets actively under development in these therapeutic areas. The company engages in the discovery and clinical advancement of novel pharmaceuticals aimed at addressing unmet medical needs in these fields. Xuanzhu Biopharmaceutical Co., Ltd. operates within the pharmaceuticals sector, contributing to advancements in treatments for gastrointestinal disorders, various cancers, and liver conditions associated with NASH. Its pipeline emphasizes targeted drug candidates designed to improve patient outcomes through precise mechanisms of action. Founded in 2017 and headquartered in Shanghai, China, Xuanzhu Biopharmaceutical Co., Ltd. plays a role in the global biopharma landscape by advancing candidates from preclinical stages through clinical trials.